United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Healthcare Industry News Is Fulgent Genetics rebuilding itself as a pathology-first diagnostics platform after losing a major customer? Fulgent Genetics targets $350M 2026 revenue as pathology expansion reshapes its customer mix. Read how the strategy could stabilise growth. byPallavi MadhirajuMarch 1, 2026